E72.02 Hartnup's disease

Name of the Condition

• Hartnup's disease (ICD-10 Code: E72.02)

Summary

Hartnup's disease is a rare genetic disorder affecting amino acid transport, particularly in the intestines and kidneys. It results in impaired absorption of neutral amino acids, leading to their excretion in urine and potential deficiencies. The condition may cause neurological and dermatological symptoms due to altered amino acid metabolism, though severity varies widely among individuals.

Causes

Hartnup's disease is caused by mutations in the SLC6A19 gene, which encodes a transporter for neutral amino acids in the intestinal and renal epithelia. These mutations disrupt normal amino acid reabsorption, leading to increased urinary excretion and reduced availability for bodily functions. The disorder follows an autosomal recessive inheritance pattern, requiring two mutated gene copies to manifest.

Risk Factors

• Family history of Hartnup's disease or related amino acid transport disorders.
• Consanguinity (parents who are close relatives) increasing recessive inheritance risk.
• Ethnic or geographic prevalence of specific SLC6A19 variants in certain populations.

Symptoms

• Neurological symptoms such as ataxia, tremors, or episodic cerebellar dysfunction.
• Dermatological manifestations like photosensitive rashes or pellagra-like skin changes.
• Gastrointestinal issues including diarrhea or malabsorption.
• Emotional or psychiatric symptoms in some cases, such as anxiety or depression.

Diagnosis

Diagnosis involves clinical evaluation of symptoms, urine amino acid analysis showing elevated neutral amino acids, and genetic testing for SLC6A19 mutations. A trial of niacin supplementation may be used to assess responsiveness, as the condition can mimic pellagra. Exclusion of other metabolic disorders is typically part of the diagnostic process.

Treatment Options

Treatment focuses on managing symptoms and preventing deficiencies. High-protein diets or supplementation with nicotinamide (a form of vitamin B3) may alleviate neurological and skin symptoms. Avoidance of triggers like sunlight or certain medications can help reduce rash episodes. Regular monitoring of nutritional status and amino acid levels is recommended.

Prognosis and Follow-Up

Prognosis is generally favorable with proper management, as many individuals remain asymptomatic or experience mild symptoms. Regular follow-up with a healthcare provider is advised to monitor for complications, adjust treatment as needed, and address any emerging neurological or dermatological issues. Early intervention can improve long-term outcomes.

Complications

Potential complications include chronic neurological impairment if left untreated, persistent skin rashes, or growth delays in children. Recurrent episodes of ataxia or psychiatric symptoms may occur without adequate management. Rarely, severe malnutrition or organ dysfunction can develop in untreated cases.

Lifestyle & Prevention

Maintaining a balanced diet rich in protein and niacin can help prevent deficiencies. Sun protection, such as sunscreen or protective clothing, may reduce skin rash frequency. Avoiding known triggers and adhering to prescribed supplementation regimens supports symptom control. Genetic counseling is recommended for families with a history of the disorder.

When to Seek Professional Help

Seek medical attention if experiencing persistent neurological symptoms (e.g., unsteady gait, confusion), severe or worsening skin rashes, or signs of malnutrition (e.g., weight loss, fatigue). Prompt evaluation is important if symptoms interfere with daily activities or if new complications arise.

Tips for Medical Coders

Document the presence of characteristic symptoms (e.g., pellagra-like rash, neurological signs) and any diagnostic testing (e.g., urine amino acid analysis, genetic results) to support coding. Ensure the code E72.02 is used only when Hartnup's disease is confirmed, as it is a specific subtype of amino acid transport disorders. Include details on treatment or management plans if relevant to the encounter.